Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A clinical trial found no difference in outcomes based on whether participants switching to Cabenuva first took oral meds for four weeks.
Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
The injectable cabotegravir, given every eight weeks, is just as effective as daily Truvada for HIV prevention.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
A majority of women interviewed in a small study expressed a preference for monthly injectable treatment over daily pills.
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
Gilead’s HIV capsid inhibitor might need dosing only every six months
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
Researchers are working on patches containing tiny needles that deliver medications through the skin.
The agency expressed concerns about the monthly injectable regimen’s chemistry and manufacturing controls.
A small study surveyed individuals about their preferences regarding long-acting injectable antiretroviral treatment.
Here are the HIV treatment news stories with the most views this year.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.